Pharma's support of Trump's drug pricing plan is fraying heading into midterms

A Trump administration plan to tie the prices of certain drugs paid for by Medicare to an international average has been met with some resistance from pharmaceutical executives, including Pfizer CEO Ian Read, heading into the midterm elections.